The "triplet therapy" is hitting advanced prostate cancer with three different attacks up front (e.g. radiation, ADT, and chemo). I think it's less common with castrate-sensitive, oligometastatic PC than it is with castrate-resistant and/or widely metastatic PC, but I am neither a medical professional nor a research scientist, so please verify with your own onco team.

ARSI (androgen-reception signal inhibitors) like Zytiga, Erleada, and Xtandi complement ADT (androgen-deprivation therapy) — the ASRI prevent the cancer cells from receiving the testosterone signal (even, to a certain extent, if once the cells have become castrate-resistant). I think it's becoming standard to prescribe both for advanced prostate cancer these days rather than just ADT alone, especially after the significant improvement demonstrated by big studies like TITAN, but they're also expensive (thousands of $$/month) if you don't have your government, private insurance, or a patient-access programme covering them.
https://www.nejm.org/doi/full/10.1056/NEJMoa1903307